ENGNW
enGene Holdings Inc. Warrants NASDAQ$1.94
Mkt Cap $99.3M
52w Low $1.90
16.7% of range
52w High $2.14
50d MA $2.52
200d MA $1.97
P/E (TTM)
-0.8x
EV/EBITDA
-3.1x
P/B
0.6x
Debt/Equity
0.2x
ROE
-43.5%
P/FCF
-3.7x
RSI (14)
—
ATR (14)
—
Beta
-0.05
50d MA
$2.52
200d MA
$1.97
Avg Volume
11.3K
About
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), wh…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 9, 2026 | AMC | -0.56 | -0.44 | +21.4% | 2.40 | +6.2% | -7.1% | -7.5% | -10.4% | +6.2% | +2.5% | — |
| Dec 22, 2025 | AMC | -0.57 | 2.71 | +578.0% | 2.90 | +0.0% | +7.2% | +8.3% | +8.3% | +6.9% | +2.1% | — |
| Sep 11, 2025 | AMC | -0.50 | 0.57 | +213.9% | — | — | — | — | — | — | — | — |
| Jun 12, 2025 | AMC | -0.50 | -0.51 | -1.7% | 0.57 | +13.3% | +13.3% | +1.1% | +34.9% | +31.4% | +26.9% | — |
| Mar 10, 2025 | AMC | -0.37 | -0.48 | -31.3% | 0.69 | -2.7% | -4.3% | -4.3% | -7.2% | +0.0% | +4.3% | — |
| Dec 19, 2024 | AMC | -0.40 | -0.03 | +92.4% | — | — | — | — | — | — | — | — |
| Sep 10, 2024 | AMC | -0.38 | -0.32 | +14.7% | — | — | — | — | — | — | — | — |
| Jun 14, 2024 | AMC | -0.26 | -0.38 | -45.8% | 1.45 | -6.3% | -13.8% | -7.9% | -12.4% | -19.3% | -17.2% | — |
| Mar 12, 2024 | AMC | -0.41 | -0.46 | -11.3% | 4.55 | +3.1% | +0.7% | -1.1% | +12.1% | +29.7% | +40.2% | — |
| Jan 29, 2024 | AMC | — | -0.34 | — | 0.87 | +4.5% | -3.4% | -6.9% | -6.9% | -6.9% | +27.6% | — |
Data updated apr 28, 2026 7:41am
· Source: massive.com